1	A	DT	4	det
2	proposed	VBN	4	amod
3	conflict-of-interest	NN	4	nn
4	policy	NN	11	nsubj
5	for	IN	4	prep
6	federally	RB	7	advmod
7	funded	VBN	9	amod
8	biomedical	JJ	9	amod
9	researchers	NNS	5	pobj
10	may	MD	11	aux
11	thwart	VB	17	ccomp
12	many	JJ	15	amod
13	high-technology	NN	15	nn
14	new	JJ	15	amod
15	ventures	NNS	11	dobj
16	,	,	17	punct
17	say	VBP	0	root
18	financiers	NNS	17	nsubj
19	,	,	18	punct
20	researchers	NNS	18	conj
21	and	CC	18	cc
22	university	NN	23	nn
23	administrators	NNS	18	conj
24	.	.	17	punct

1	The	DT	6	det
2	National	NNP	6	dep
3	Institutes	NNPS	2	dep
4	of	IN	2	prep
5	Health	NNP	4	pobj
6	policy	NN	8	nsubj
7	would	MD	8	aux
8	require	VB	0	root
9	researchers	NNS	11	nsubj
10	to	TO	11	aux
11	cut	VB	8	xcomp
12	financial	JJ	13	amod
13	ties	NNS	11	dobj
14	with	IN	13	prep
15	health-care	JJ	16	amod
16	businesses	NNS	14	pobj
17	--	:	11	punct
18	or	CC	11	cc
19	lose	VB	11	conj
20	their	PRP$	22	poss
21	government	NN	22	nn
22	money	NN	19	dobj
23	.	.	8	punct

1	Among	IN	7	prep
2	other	JJ	3	amod
3	concerns	NNS	1	pobj
4	,	,	7	punct
5	the	DT	6	det
6	agency	NN	7	nsubj
7	says	VBZ	0	root
8	researchers	NNS	14	nsubj
9	with	IN	8	prep
10	business	NN	11	nn
11	ties	NNS	9	pobj
12	are	VBP	14	cop
13	more	RBR	14	advmod
14	likely	JJ	7	ccomp
15	to	TO	16	aux
16	falsify	VB	14	xcomp
17	findings	NNS	16	dobj
18	in	IN	21	mark
19	order	NN	21	dep
20	to	TO	21	aux
21	tout	VB	16	purpcl
22	new	JJ	23	amod
23	drugs	NNS	21	dobj
24	.	.	7	punct

1	As	IN	9	mark
2	ties	NNS	9	nsubj
3	between	IN	2	prep
4	academia	NN	3	pobj
5	and	CC	4	cc
6	venture	NN	7	nn
7	capital	NN	4	conj
8	have	VBP	9	aux
9	blossomed	VBN	19	advcl
10	in	IN	9	prep
11	recent	JJ	12	amod
12	years	NNS	10	pobj
13	,	,	19	punct
14	governmental	JJ	15	amod
15	fear	NN	19	nsubj
16	of	IN	15	prep
17	abuse	NN	16	pobj
18	has	VBZ	19	aux
19	risen	VBN	0	root
20	.	.	19	punct

1	But	CC	6	cc
2	the	DT	3	det
3	guidelines	NNS	6	nsubj
4	could	MD	6	aux
5	``	``	6	punct
6	make	VB	14	ccomp
7	it	PRP	10	nsubj
8	impossible	JJ	10	dep
9	to	TO	10	aux
10	commercialize	VB	6	xcomp
11	research	NN	10	dobj
12	,	,	14	punct
13	''	''	14	punct
14	says	VBZ	0	root
15	Kenneth	NNP	16	nn
16	Smith	NNP	14	nsubj
17	,	,	16	punct
18	associate	JJ	19	amod
19	provost	NN	16	appos
20	and	CC	19	cc
21	vice	NN	22	nn
22	president	NN	19	conj
23	for	IN	22	prep
24	research	NN	23	pobj
25	at	IN	19	prep
26	Massachusetts	NNP	27	nn
27	Institute	NNP	25	pobj
28	of	IN	27	prep
29	Technology	NNP	28	pobj
30	.	.	14	punct

1	The	DT	2	det
2	NIH	NNP	4	nsubj
3	is	VBZ	4	aux
4	asking	VBG	0	root
5	grant	NN	6	nn
6	recipients	NNS	4	dobj
7	and	CC	6	cc
8	others	NNS	6	conj
9	for	IN	4	prep
10	comments	NNS	9	pobj
11	on	IN	10	prep
12	the	DT	14	det
13	proposed	VBN	14	amod
14	guidelines	NNS	11	pobj
15	until	IN	4	prep
16	Dec.	NNP	15	pobj
17	15	CD	16	num
18	.	.	4	punct

1	After	IN	6	prep
2	that	DT	1	pobj
3	,	,	6	punct
4	it	PRP	6	nsubj
5	will	MD	6	aux
6	make	VB	0	root
7	a	DT	9	det
8	final	JJ	9	amod
9	decision	NN	6	dobj
10	on	IN	9	prep
11	the	DT	12	det
12	policy	NN	10	pobj
13	.	.	6	punct

1	The	DT	2	det
2	guidelines	NNS	4	nsubj
3	could	MD	4	aux
4	foil	VB	22	ccomp
5	future	JJ	6	amod
6	arrangements	NNS	4	dobj
7	similar	JJ	6	amod
8	to	TO	7	prep
9	the	DT	10	det
10	deal	NN	8	pobj
11	behind	IN	10	prep
12	Lithox	NNP	13	nn
13	Inc.	NNP	11	pobj
14	,	,	13	punct
15	a	DT	20	det
16	Salem	NNP	20	dep
17	,	,	16	punct
18	Mass.	NNP	16	dep
19	,	,	16	punct
20	start-up	NN	13	appos
21	,	,	22	punct
22	says	VBZ	0	root
23	Robert	NNP	24	nn
24	Daly	NNP	22	nsubj
25	,	,	24	punct
26	a	DT	28	det
27	managing	VBG	28	amod
28	partner	NN	24	appos
29	of	IN	28	prep
30	TA	NNP	31	nn
31	Associates	NNPS	29	pobj
32	,	,	31	punct
33	a	DT	35	det
34	venture-capital	JJ	35	amod
35	firm	NN	31	appos
36	.	.	22	punct

1	With	IN	10	prep
2	$	$	1	pobj
3	2.3	CD	2	number
4	million	CD	2	number
5	,	,	10	punct
6	he	PRP	10	nsubj
7	and	CC	6	cc
8	other	JJ	9	amod
9	investors	NNS	6	conj
10	launched	VBD	0	root
11	Lithox	NNP	10	dobj
12	last	JJ	13	amod
13	year	NN	10	tmod
14	to	TO	15	aux
15	market	NN	10	xcomp
16	a	DT	18	det
17	gallstone	NN	18	nn
18	cure	NN	15	dobj
19	being	NN	20	dep
20	developed	VBN	18	dep
21	by	IN	20	prep
22	researchers	NNS	21	pobj
23	of	IN	22	prep
24	the	DT	25	det
25	University	NNP	23	pobj
26	of	IN	25	prep
27	California	NNP	26	pobj
28	at	IN	25	prep
29	San	NNP	30	nn
30	Diego	NNP	28	pobj
31	.	.	10	punct

1	The	DT	2	det
2	researchers	NNS	14	nsubj
3	,	,	2	punct
4	who	WP	7	nsubjpass
5	are	VBP	7	aux
6	being	VBG	7	auxpass
7	financed	VBN	2	rcmod
8	by	IN	7	prep
9	the	DT	11	det
10	Lithox	NNP	11	nn
11	funds	NNS	8	pobj
12	,	,	2	punct
13	will	MD	14	aux
14	receive	VB	0	root
15	a	DT	19	det
16	royalty	NN	19	conj
17	,	,	19	punct
18	or	CC	19	cc
19	percentage	NN	14	dobj
20	of	IN	19	prep
21	sales	NNS	20	pobj
22	,	,	19	punct
23	if	IN	26	mark
24	their	PRP$	25	poss
25	research	NN	26	nsubj
26	yields	VBZ	14	advcl
27	a	DT	29	det
28	commercial	JJ	29	amod
29	product	NN	26	dobj
30	.	.	14	punct

1	But	CC	21	cc
2	because	IN	13	mark
3	the	DT	4	det
4	University	NNP	13	nsubj
5	of	IN	4	prep
6	California	NNP	5	pobj
7	,	,	13	punct
8	like	IN	13	prep
9	many	JJ	11	amod
10	other	JJ	11	amod
11	universities	NNS	8	pobj
12	,	,	13	punct
13	shares	VBZ	21	advcl
14	its	PRP$	15	poss
15	royalties	NNS	13	dobj
16	with	IN	13	prep
17	researchers	NNS	16	pobj
18	,	,	21	punct
19	it	PRP	21	nsubj
20	may	MD	21	aux
21	disqualify	VB	33	dep
22	itself	PRP	21	dobj
23	from	IN	21	prep
24	federal	JJ	25	amod
25	funds	NNS	23	pobj
26	under	IN	21	prep
27	the	DT	29	det
28	proposed	VBN	29	amod
29	guidelines	NNS	26	pobj
30	,	,	21	punct
31	Mr.	NNP	32	nn
32	Daly	NNP	33	nsubj
33	says	VBZ	0	root
34	.	.	33	punct

1	The	DT	3	det
2	high-tech	JJ	3	amod
3	industry	NN	5	nsubj
4	is	VBZ	5	cop
5	full	JJ	0	root
6	of	IN	5	prep
7	the	DT	8	det
8	kind	NN	6	pobj
9	of	IN	8	prep
10	arrangement	NN	9	pobj
11	that	IN	16	dobj
12	the	DT	14	det
13	new	JJ	14	amod
14	guidelines	NNS	16	nsubj
15	would	MD	16	aux
16	affect	VB	8	rcmod
17	.	.	5	punct

1	For	IN	14	prep
2	instance	NN	1	pobj
3	,	,	14	punct
4	Commonwealth	NNP	5	nn
5	BioVentures	NNP	6	nn
6	Inc.	NNP	14	nsubj
7	,	,	6	punct
8	a	DT	10	det
9	venture-capital	JJ	10	amod
10	concern	NN	6	appos
11	,	,	6	punct
12	last	JJ	13	amod
13	month	NN	14	tmod
14	invested	VBD	0	root
15	$	$	14	dobj
16	600,000	CD	15	num
17	to	TO	18	aux
18	launch	VB	14	xcomp
19	Amira	NNP	20	nn
20	Inc.	NNP	18	dobj
21	,	,	20	punct
22	a	DT	27	det
23	Worcester	NNP	27	dep
24	,	,	23	punct
25	Mass.	NNP	23	dep
26	,	,	23	punct
27	concern	NN	20	appos
28	that	WDT	30	nsubj
29	will	MD	30	aux
30	produce	VB	27	rcmod
31	pharmaceuticals	NNS	30	dobj
32	.	.	14	punct

1	Scientists	NNS	3	dep
2	Rima	NNP	3	nn
3	Kaddurah-Daouk	NNP	7	nsubj
4	and	CC	3	cc
5	Paul	NNP	6	nn
6	Schimmel	NNP	3	conj
7	conducted	VBD	0	root
8	the	DT	10	det
9	initial	JJ	10	amod
10	research	NN	7	dobj
11	at	IN	7	prep
12	the	DT	14	det
13	Massachusetts	NNP	14	nn
14	Institute	NNP	11	pobj
15	of	IN	14	prep
16	Technology	NNP	15	pobj
17	.	.	7	punct

1	While	IN	4	mark
2	Ms.	NNP	3	nn
3	Kaddurah-Daouk	NNP	4	nsubj
4	left	VBD	13	advcl
5	MIT	NNP	4	dobj
6	to	TO	7	aux
7	head	VB	4	xcomp
8	Amira	NNP	7	dobj
9	,	,	13	punct
10	Prof.	NNP	11	nn
11	Schimmel	NNP	13	nsubj
12	will	MD	13	aux
13	continue	VB	0	root
14	to	TO	15	aux
15	work	VB	13	xcomp
16	at	IN	15	prep
17	MIT	NNP	16	pobj
18	,	,	15	punct
19	serve	VB	15	conj
20	on	IN	19	prep
21	Amira	NNP	23	poss
22	's	POS	21	possessive
23	board	NN	20	pobj
24	and	CC	15	cc
25	own	VB	15	conj
26	a	DT	29	det
27	small	JJ	29	amod
28	equity	NN	29	nn
29	stake	NN	25	dobj
30	in	IN	29	prep
31	the	DT	32	det
32	company	NN	30	pobj
33	.	.	13	punct

1	The	DT	3	det
2	Amira	NNP	3	nn
3	transaction	NN	5	nsubj
4	is	VBZ	5	cop
5	typical	JJ	0	root
6	of	IN	5	prep
7	the	DT	8	det
8	way	NN	6	pobj
9	venture-capital	JJ	10	amod
10	firms	NNS	12	nsubj
11	are	VBP	12	aux
12	approaching	VBG	8	rcmod
13	the	DT	14	det
14	task	NN	12	dobj
15	of	IN	14	prep
16	commercializing	VBG	15	pcomp
17	biotechnology	NN	18	nn
18	research	NN	16	dobj
19	.	.	5	punct

1	While	IN	3	mark
2	universities	NNS	3	nsubj
3	develop	VBP	13	advcl
4	the	DT	6	det
5	basic	JJ	6	amod
6	research	NN	3	dobj
7	,	,	13	punct
8	``	``	13	punct
9	venture	NN	10	nn
10	capitalists	NNS	13	nsubj
11	are	VBP	13	cop
12	the	DT	13	det
13	ones	NNS	22	ccomp
14	best	RB	15	advmod
15	positioned	VBD	13	partmod
16	to	TO	17	aux
17	finance	VB	15	xcomp
18	its	PRP$	19	poss
19	commercialization	NN	17	dobj
20	,	,	22	punct
21	''	''	22	punct
22	says	VBZ	0	root
23	Gloria	NNP	25	nn
24	W.	NNP	25	nn
25	Doubleday	NNP	22	nsubj
26	of	IN	25	prep
27	Commonwealth	NNP	26	pobj
28	.	.	22	punct

1	``	``	6	punct
2	This	DT	6	nsubj
3	is	VBZ	6	cop
4	the	DT	6	det
5	best	JJS	6	amod
6	way	NN	0	root
7	to	TO	8	aux
8	transfer	VB	6	infmod
9	technology	NN	8	dobj
10	straight	RB	11	advmod
11	off	IN	8	prep
12	the	DT	13	det
13	campuses	NNS	11	pobj
14	of	IN	13	prep
15	universities	NNS	14	pobj
16	.	.	6	punct
17	''	''	6	punct

1	But	CC	6	cc
2	the	DT	4	det
3	new	JJ	4	amod
4	guidelines	NNS	6	nsubj
5	could	MD	6	aux
6	prevent	VB	22	dep
7	scientists	NNS	6	dobj
8	like	IN	7	prep
9	Prof.	NNP	10	nn
10	Schimmel	NNP	8	pobj
11	from	IN	6	prep
12	being	VBG	13	auxpass
13	involved	VBN	11	pcomp
14	with	IN	13	prep
15	start-ups	NNS	14	pobj
16	such	JJ	17	mwe
17	as	IN	15	prep
18	Amira	NNP	17	pobj
19	,	,	6	punct
20	venture	NN	21	nn
21	capitalists	NNS	22	nsubj
22	point	VBP	0	root
23	out	RP	22	prt
24	.	.	22	punct

1	And	CC	17	cc
2	if	IN	4	mark
3	that	DT	4	nsubj
4	happens	VBZ	17	advcl
5	,	,	17	punct
6	the	DT	8	det
7	entire	JJ	8	amod
8	process	NN	17	nsubjpass
9	of	IN	8	prep
10	transferring	VBG	9	pcomp
11	technology	NN	10	dobj
12	to	TO	10	prep
13	the	DT	14	det
14	marketplace	NN	12	pobj
15	could	MD	17	aux
16	be	VB	17	auxpass
17	harmed	VBN	20	dep
18	,	,	17	punct
19	they	PRP	20	nsubj
20	say	VBP	0	root
21	.	.	20	punct

1	The	DT	2	det
2	stakes	NNS	7	nsubj
3	in	IN	2	prep
4	the	DT	5	det
5	controversy	NN	3	pobj
6	are	VBP	7	cop
7	large	JJ	0	root
8	.	.	7	punct

1	Last	JJ	2	amod
2	year	NN	6	tmod
3	,	,	6	punct
4	venture	NN	5	nn
5	capitalists	NNS	6	nsubj
6	spent	VBD	0	root
7	an	DT	9	det
8	estimated	VBN	9	dep
9	$	$	6	dobj
10	600	CD	9	number
11	million	CD	9	number
12	to	TO	13	aux
13	finance	VB	6	xcomp
14	start-up	JJ	15	amod
15	companies	NNS	13	dobj
16	in	IN	13	prep
17	medical	JJ	20	amod
18	and	CC	17	cc
19	biotechnology	NN	17	conj
20	businesses	NNS	16	pobj
21	,	,	6	punct
22	according	VBG	6	prep
23	to	TO	22	pcomp
24	the	DT	28	det
25	National	NNP	28	nn
26	Venture	NNP	27	nn
27	Capital	NNP	28	nn
28	Association	NNP	23	pobj
29	,	,	28	punct
30	a	DT	32	det
31	trade	NN	32	nn
32	group	NN	28	appos
33	.	.	6	punct

1	Many	JJ	5	nsubj
2	of	IN	1	prep
3	the	DT	4	det
4	deals	NNS	2	pobj
5	involved	VBD	0	root
6	transactions	NNS	5	dobj
7	in	IN	13	rel
8	which	WDT	7	pobj
9	scientific	JJ	10	amod
10	institutions	NNS	13	nsubj
11	or	CC	10	cc
12	researchers	NNS	10	conj
13	agreed	VBN	6	rcmod
14	to	TO	15	aux
15	commercialize	VB	13	xcomp
16	their	PRP$	17	poss
17	work	NN	15	dobj
18	in	IN	13	prep
19	return	NN	18	pobj
20	for	IN	19	prep
21	an	DT	23	det
22	equity	NN	23	nn
23	stake	NN	20	pobj
24	or	CC	23	cc
25	royalties	NNS	23	conj
26	.	.	5	punct

1	In	IN	10	prep
2	many	DT	1	pobj
3	of	IN	2	prep
4	these	DT	3	pobj
5	deals	VBZ	4	dep
6	,	,	10	punct
7	``	``	10	punct
8	venture	NN	9	nn
9	capitalists	NNS	10	nsubj
10	had	VBD	16	ccomp
11	the	DT	13	det
12	inside	NN	13	nn
13	track	NN	10	dobj
14	,	,	16	punct
15	''	''	16	punct
16	says	VBZ	0	root
17	Lawrence	NNP	18	nn
18	Bock	NNP	16	nsubj
19	of	IN	18	prep
20	Avalon	NNP	21	nn
21	Ventures	NNP	19	pobj
22	,	,	21	punct
23	La	NNP	24	nn
24	Jolla	NNP	21	appos
25	,	,	24	punct
26	Calif	NNP	24	appos
27	.	.	16	punct

1	Investors	NNS	3	nsubj
2	were	VBD	3	cop
3	willing	JJ	21	ccomp
4	to	TO	5	aux
5	gamble	VB	3	xcomp
6	on	IN	5	prep
7	new	JJ	8	amod
8	technologies	NNS	6	pobj
9	because	IN	12	mark
10	``	``	12	punct
11	we	PRP	12	nsubj
12	had	VBD	5	advcl
13	exclusive	JJ	14	amod
14	rights	NNS	12	dobj
15	to	TO	14	prep
16	those	DT	17	det
17	technologies	NNS	15	pobj
18	,	,	21	punct
19	''	''	21	punct
20	he	PRP	21	nsubj
21	adds	VBZ	0	root
22	.	.	21	punct

1	But	CC	12	cc
2	under	IN	12	prep
3	the	DT	5	det
4	proposed	VBN	5	amod
5	guidelines	NNS	2	pobj
6	,	,	12	punct
7	all	DT	10	det
8	federally	RB	9	advmod
9	funded	VBN	10	amod
10	research	NN	12	nsubj
11	will	MD	12	aux
12	have	VB	0	root
13	to	TO	15	aux
14	be	VB	15	auxpass
15	reported	VBN	12	xcomp
16	publicly	RB	15	advmod
17	so	IN	21	mark
18	that	IN	21	dep
19	anyone	NN	21	nsubj
20	can	MD	21	aux
21	capitalize	VB	15	advcl
22	on	IN	21	prep
23	the	DT	24	det
24	work	NN	22	pobj
25	.	.	12	punct

1	``	``	23	punct
2	Without	IN	11	prep
3	the	DT	4	det
4	exclusivity	NN	2	pobj
5	,	,	11	punct
6	most	JJS	8	amod
7	venture	NN	8	nn
8	capitalists	NNS	11	nsubj
9	wo	MD	11	aux
10	n't	RB	11	neg
11	have	VB	23	ccomp
12	the	DT	13	det
13	incentive	NN	11	dobj
14	to	TO	15	aux
15	invest	VB	13	infmod
16	in	IN	15	prep
17	such	JJ	18	amod
18	deals	NNS	16	pobj
19	,	,	23	punct
20	''	''	23	punct
21	Mr.	NNP	22	nn
22	Bock	NNP	23	nsubj
23	says	VBZ	0	root
24	.	.	23	punct

1	Last	JJ	2	amod
2	year	NN	10	tmod
3	,	,	10	punct
4	for	IN	10	prep
5	example	NN	4	pobj
6	,	,	10	punct
7	Avalon	NNP	10	nsubj
8	and	CC	7	cc
9	others	NNS	7	conj
10	invested	VBD	0	root
11	$	$	10	dobj
12	14	CD	11	number
13	million	CD	11	number
14	in	IN	10	prep
15	Athena	NNP	16	nn
16	Neurosciences	NNP	17	nn
17	Inc.	NNP	14	pobj
18	,	,	17	punct
19	South	NNP	21	nn
20	San	NNP	21	nn
21	Francisco	NNP	17	appos
22	,	,	21	punct
23	Calif.	NNP	21	appos
24	,	,	10	punct
25	to	TO	26	aux
26	license	VB	10	xcomp
27	and	CC	26	cc
28	develop	VB	26	conj
29	technology	NN	26	dobj
30	for	IN	29	prep
31	delivery	NN	30	pobj
32	of	IN	31	prep
33	drugs	NNS	32	pobj
34	to	TO	31	prep
35	the	DT	36	det
36	brain	NN	34	pobj
37	.	.	10	punct

1	But	CC	18	cc
2	before	IN	5	mark
3	Athena	NNP	5	nsubj
4	was	VBD	5	cop
5	able	JJ	18	advcl
6	to	TO	7	aux
7	get	VB	5	xcomp
8	an	DT	10	det
9	exclusive	JJ	10	amod
10	license	NN	7	dobj
11	to	TO	10	prep
12	the	DT	13	det
13	technology	NN	11	pobj
14	,	,	18	punct
15	the	DT	17	det
16	Federal	NNP	17	nn
17	Register	NNP	18	nsubj
18	published	VBD	42	ccomp
19	most	JJS	18	dobj
20	of	IN	19	prep
21	the	DT	22	det
22	details	NNS	20	pobj
23	,	,	18	punct
24	``	``	18	punct
25	giving	VBG	18	xcomp
26	all	DT	25	iobj
27	of	IN	26	prep
28	the	DT	29	det
29	company	NN	32	poss
30	's	POS	29	possessive
31	potential	JJ	32	amod
32	competitors	NNS	27	pobj
33	a	DT	34	det
34	chance	NN	25	dobj
35	to	TO	36	aux
36	exploit	VB	34	infmod
37	it	PRP	36	dobj
38	,	,	42	punct
39	''	''	42	punct
40	Mr.	NNP	41	nn
41	Bock	NNP	42	nsubj
42	says	VBZ	0	root
43	.	.	42	punct

1	Athena	NNP	3	nsubj
2	eventually	RB	3	advmod
3	acquired	VBD	0	root
4	exclusive	JJ	5	amod
5	rights	NNS	3	dobj
6	to	TO	5	prep
7	the	DT	8	det
8	technology	NN	6	pobj
9	and	CC	3	cc
10	currently	RB	12	advmod
11	is	VBZ	12	aux
12	developing	VBG	3	conj
13	it	PRP	12	dobj
14	.	.	3	punct

1	But	CC	3	cc
2	,	,	3	punct
3	says	VBZ	0	root
4	Mr.	NNP	5	nn
5	Bock	NNP	3	nsubj
6	,	,	3	punct
7	``	``	3	punct
8	It	PRP	12	nsubj
9	was	VBD	12	cop
10	a	DT	12	det
11	close	JJ	12	amod
12	call	NN	3	ccomp
13	.	.	3	punct
14	''	''	3	punct

1	The	DT	3	det
2	proposed	VBN	3	amod
3	guidelines	NNS	6	nsubj
4	could	MD	6	aux
5	also	RB	6	advmod
6	delay	VB	19	ccomp
7	commercialization	NN	6	dobj
8	--	:	6	punct
9	and	CC	6	cc
10	force	VB	6	conj
11	small	JJ	12	amod
12	companies	NNS	14	nsubj
13	to	TO	14	aux
14	waste	VB	10	xcomp
15	scarce	JJ	16	amod
16	capital	NN	14	dobj
17	,	,	19	punct
18	entrepreneurs	NNS	19	nsubj
19	say	VBP	0	root
20	.	.	19	punct

1	If	IN	5	mark
2	start-ups	NNS	5	nsubj
3	ca	MD	5	aux
4	n't	RB	5	neg
5	have	VB	17	advcl
6	early	JJ	7	amod
7	access	NN	5	dobj
8	to	TO	7	prep
9	research	NN	8	pobj
10	being	NN	11	dep
11	conducted	VBN	9	dep
12	at	IN	11	prep
13	institutions	NNS	12	pobj
14	,	,	17	punct
15	``	``	17	punct
16	we	PRP	17	nsubj
17	have	VBP	29	ccomp
18	to	TO	19	aux
19	replicate	VB	17	xcomp
20	it	PRP	19	dobj
21	ourselves	PRP	19	npadvmod
22	or	CC	19	cc
23	do	VB	19	conj
24	without	IN	23	prep
25	the	DT	26	det
26	research	NN	24	pobj
27	,	,	29	punct
28	''	''	29	punct
29	says	VBZ	0	root
30	Ruth	NNP	31	nn
31	Emyanitoff	NNP	29	nsubj
32	,	,	31	punct
33	manager	NN	31	appos
34	of	IN	33	prep
35	business	NN	36	nn
36	development	NN	34	pobj
37	at	IN	33	prep
38	Applied	NNP	39	nn
39	bioTechnology	NNP	40	nn
40	Inc.	NNP	37	pobj
41	,	,	40	punct
42	a	DT	47	det
43	Cambridge	NNP	47	dep
44	,	,	43	punct
45	Mass.	NNP	43	dep
46	,	,	43	punct
47	concern	NN	40	appos
48	.	.	29	punct

1	Duplicating	VBG	5	csubj
2	research	NN	1	dobj
3	is	VBZ	5	cop
4	both	DT	5	preconj
5	costly	JJ	14	ccomp
6	and	CC	5	cc
7	time-consuming	JJ	5	conj
8	for	IN	5	prep
9	a	DT	10	det
10	start-up	NN	8	pobj
11	,	,	14	punct
12	Ms.	NNP	13	nn
13	Emyanitoff	NNP	14	nsubj
14	says	VBZ	0	root
15	.	.	14	punct

1	For	IN	6	prep
2	its	PRP$	3	poss
3	part	NN	1	pobj
4	,	,	6	punct
5	NIH	NNP	6	nsubj
6	insists	VBZ	0	root
7	that	IN	13	complm
8	its	PRP$	9	poss
9	guidelines	NNS	13	nsubj
10	``	``	13	punct
11	should	MD	13	aux
12	not	RB	13	neg
13	stifle	VB	6	ccomp
14	research	NN	15	nn
15	creativity	NN	13	dobj
16	or	CC	15	cc
17	technology	NN	18	nn
18	transfer	NN	15	conj
19	from	IN	18	prep
20	the	DT	22	det
21	research	NN	22	nn
22	laboratory	NN	19	pobj
23	to	TO	18	prep
24	commercial	JJ	25	amod
25	use	NN	23	pobj
26	.	.	6	punct
27	''	''	6	punct

1	Universities	NNS	9	nsubj
2	such	JJ	3	mwe
3	as	IN	1	prep
4	Harvard	NNP	3	pobj
5	and	CC	4	cc
6	MIT	NNP	4	conj
7	should	MD	9	aux
8	be	VB	9	cop
9	able	JJ	23	ccomp
10	to	TO	11	aux
11	develop	VB	9	xcomp
12	a	DT	13	det
13	way	NN	11	dobj
14	to	TO	15	aux
15	act	VB	13	infmod
16	as	IN	15	prep
17	brokers	NNS	16	pobj
18	for	IN	17	prep
19	the	DT	21	det
20	individual	JJ	21	amod
21	scientists	NNS	18	pobj
22	,	,	23	punct
23	says	VBZ	0	root
24	Katherine	NNP	25	nn
25	Bick	NNP	23	nsubj
26	,	,	25	punct
27	who	WP	28	nsubj
28	oversees	VBZ	25	rcmod
29	the	DT	33	det
30	huge	JJ	33	amod
31	NIH	NNP	33	nn
32	grants	NNS	33	nn
33	program	NN	28	dobj
34	as	IN	28	prep
35	its	PRP$	37	poss
36	deputy	NN	37	nn
37	director	NN	34	pobj
38	for	IN	37	prep
39	extramural	JJ	40	amod
40	research	NN	38	pobj
41	.	.	23	punct

1	NIH	NNP	3	nn
2	staff	NN	3	nn
3	members	NNS	4	nsubj
4	believe	VBP	0	root
5	the	DT	6	det
6	guidelines	NNS	8	nsubj
7	are	VBP	8	cop
8	essential	JJ	4	ccomp
9	to	TO	10	aux
10	prevent	VB	8	xcomp
11	the	DT	12	det
12	escalation	NN	10	dobj
13	of	IN	12	prep
14	problems	NNS	13	pobj
15	that	WDT	18	nsubj
16	have	VBP	18	aux
17	already	RB	18	advmod
18	begun	VBN	14	rcmod
19	to	TO	20	aux
20	surface	VB	18	xcomp
21	in	IN	20	prep
22	scientific	JJ	23	amod
23	ventures	NNS	21	pobj
24	.	.	4	punct

1	Not	RB	3	dep
2	long	RB	3	advmod
3	ago	RB	14	advmod
4	,	,	14	punct
5	scientists	NNS	14	nsubjpass
6	holding	VBG	5	partmod
7	stock	NN	6	dobj
8	in	IN	7	prep
9	Spectra	NNP	11	nn
10	Pharmaceutical	NNP	11	nn
11	Services	NNPS	12	nn
12	Inc.	NNP	8	pobj
13	were	VBD	14	auxpass
14	accused	VBN	0	root
15	of	IN	14	prep
16	falsifying	VBG	15	pcomp
17	research	NN	16	dobj
18	to	TO	19	aux
19	boost	VB	16	xcomp
20	the	DT	21	det
21	stock	NN	19	dobj
22	.	.	14	punct

1	Many	JJ	2	amod
2	officials	NNS	5	nsubjpass
3	are	VBP	5	auxpass
4	also	RB	5	advmod
5	concerned	VBN	0	root
6	about	IN	5	prep
7	companies	NNS	6	pobj
8	getting	VBG	7	partmod
9	a	DT	12	det
10	``	``	12	punct
11	free	JJ	12	amod
12	ride	NN	8	dobj
13	''	''	12	punct
14	on	IN	12	prep
15	government-sponsored	JJ	16	amod
16	research	NN	14	pobj
17	.	.	5	punct

1	A	DT	3	det
2	congressional	JJ	3	amod
3	subcommitee	NN	6	nsubj
4	has	VBZ	6	aux
5	been	VBN	6	aux
6	investigating	VBG	0	root
7	the	DT	9	det
8	potential	JJ	9	amod
9	abuse	NN	6	dobj
10	from	IN	9	prep
11	researchers	NNS	10	pobj
12	holding	VBG	11	partmod
13	stock	NN	12	dobj
14	in	IN	13	prep
15	companies	NNS	14	pobj
16	exploiting	VBG	15	partmod
17	their	PRP$	18	poss
18	research	NN	16	dobj
19	.	.	6	punct

1	Among	IN	9	prep
2	other	JJ	3	amod
3	provisions	NNS	1	pobj
4	,	,	9	punct
5	the	DT	7	det
6	NIH	NNP	7	nn
7	guidelines	NNS	9	nsubj
8	would	MD	9	aux
9	prohibit	VB	0	root
10	researchers	NNS	9	dobj
11	and	CC	10	cc
12	members	NNS	10	conj
13	of	IN	12	prep
14	their	PRP$	16	poss
15	immediate	JJ	16	amod
16	families	NNS	13	pobj
17	from	IN	9	prep
18	holding	VBG	17	pcomp
19	stock	NN	18	dobj
20	in	IN	19	prep
21	any	DT	22	det
22	company	NN	20	pobj
23	that	WDT	25	nsubjpass
24	is	VBZ	25	auxpass
25	affected	VBN	22	rcmod
26	by	IN	25	prep
27	the	DT	28	det
28	outcome	NN	26	pobj
29	of	IN	28	prep
30	their	PRP$	31	poss
31	research	NN	29	pobj
32	.	.	9	punct

1	Ms.	NNP	2	nn
2	Bick	NNP	8	nsubj
3	,	,	2	punct
4	the	DT	6	det
5	NIH	NNP	6	nn
6	administrator	NN	2	appos
7	,	,	2	punct
8	says	VBZ	0	root
9	the	DT	13	det
10	business	NN	13	nn
11	and	CC	10	cc
12	scientific	JJ	10	conj
13	community	NN	15	nsubj
14	is	VBZ	15	aux
15	overreacting	VBG	8	ccomp
16	to	TO	15	prep
17	what	WP	21	dep
18	the	DT	19	det
19	agency	NN	21	nsubj
20	merely	RB	21	advmod
21	meant	VBD	16	pcomp
22	to	TO	25	aux
23	be	VB	25	cop
24	``	``	25	punct
25	ideas	NNS	21	xcomp
26	for	IN	25	prep
27	discussion	NN	26	pobj
28	.	.	8	punct
29	''	''	8	punct

1	The	DT	2	det
2	predictions	NNS	7	nsubj
3	of	IN	2	prep
4	doom	NN	3	pobj
5	are	VBP	7	cop
6	``	``	7	punct
7	premature	JJ	11	ccomp
8	,	,	11	punct
9	''	''	11	punct
10	she	PRP	11	nsubj
11	says	VBZ	0	root
12	.	.	11	punct

1	But	CC	14	cc
2	when	WRB	7	advmod
3	agencies	NNS	7	nsubj
4	like	IN	3	prep
5	the	DT	6	det
6	NIH	NNP	4	pobj
7	circulate	VBP	14	advcl
8	guidelines	NNS	7	dobj
9	,	,	14	punct
10	they	PRP	14	nsubj
11	've	VBP	14	aux
12	often	RB	14	advmod
13	already	RB	14	advmod
14	formulated	VBN	19	ccomp
15	policy	NN	14	dobj
16	,	,	19	punct
17	veteran	NN	18	nn
18	scientists	NNS	19	nsubj
19	say	VBP	0	root
20	.	.	19	punct

1	Indeed	RB	6	advmod
2	,	,	6	punct
3	institutions	NNS	6	nsubj
4	already	RB	6	advmod
5	are	VBP	6	aux
6	taking	VBG	0	root
7	note	NN	6	dobj
8	.	.	6	punct

1	On	IN	6	prep
2	Sept.	NNP	1	pobj
3	14	CD	2	num
4	,	,	6	punct
5	Harvard	NNP	6	nsubj
6	began	VBD	0	root
7	circulating	VBG	6	xcomp
8	a	DT	11	det
9	conflict-of-interest	JJ	10	amod
10	policy	NN	11	nn
11	statement	NN	7	dobj
12	that	IN	18	nsubj
13	,	,	18	punct
14	in	IN	18	prep
15	effect	NN	14	pobj
16	,	,	18	punct
17	would	MD	18	aux
18	follow	VB	11	rcmod
19	the	DT	21	det
20	NIH	NNP	21	nn
21	guidelines	NNS	18	dobj
22	faithfully	RB	18	advmod
23	.	.	6	punct

1	The	DT	2	det
2	University	NNP	10	nsubj
3	of	IN	2	prep
4	California	NNP	3	pobj
5	at	IN	2	prep
6	San	NNP	7	nn
7	Francisco	NNP	5	pobj
8	is	VBZ	10	aux
9	also	RB	10	advmod
10	circulating	VBG	0	root
11	a	DT	12	det
12	memo	NN	10	dobj
13	among	IN	10	prep
14	its	PRP$	16	poss
15	scientific	JJ	16	amod
16	faculty	NN	13	pobj
17	that	WDT	19	nsubj
18	will	MD	19	aux
19	restrict	VB	10	dep
20	contact	NN	19	dobj
21	with	IN	20	prep
22	the	DT	23	det
23	world	NN	21	pobj
24	of	IN	23	prep
25	business	NN	24	pobj
26	.	.	10	punct

1	In	IN	8	prep
2	many	JJ	4	amod
3	other	JJ	4	amod
4	institutions	NNS	1	pobj
5	,	,	8	punct
6	scientists	NNS	8	nsubj
7	are	VBP	8	aux
8	shunning	VBG	0	root
9	contacts	NNS	8	dobj
10	with	IN	9	prep
11	venture	NN	12	nn
12	investors	NNS	10	pobj
13	until	IN	18	mark
14	the	DT	16	det
15	NIH	NNP	16	nn
16	policy	NN	18	nsubjpass
17	is	VBZ	18	auxpass
18	settled	VBN	8	advcl
19	.	.	8	punct

1	Says	VBZ	0	root
2	Mr.	NNP	3	nn
3	Daly	NNP	1	nsubj
4	,	,	3	punct
5	the	DT	7	det
6	venture	NN	7	nn
7	capitalist	NN	3	appos
8	:	:	1	punct
9	``	``	1	punct
10	It	PRP	13	nsubj
11	does	VBZ	13	aux
12	n't	RB	13	neg
13	matter	VB	1	ccomp
14	whether	IN	16	complm
15	they	PRP	16	nsubj
16	call	VBP	13	ccomp
17	it	PRP	18	nsubj
18	guidelines	NNS	16	xcomp
19	or	CC	18	cc
20	policy	NN	18	conj
21	.	.	1	punct

1	The	DT	2	det
2	damage	NN	5	nsubjpass
3	is	VBZ	5	auxpass
4	already	RB	5	advmod
5	done	VBN	0	root
6	.	.	5	punct


